Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology

Georgios K. Eleftheriadis, Christos S. Katsiotis, Natalja Genina, Johan Boetker, Jukka Rantanen*, Dimitrios G. Fatouros

*Corresponding author for this work

Research output: Contribution to journalEditorialResearch

24 Citations (Scopus)
141 Downloads (Pure)

Abstract

The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical compounds is a recent approach to develop complex and custom-made drug delivery systems (DDSs). However, the FFF technology is characterized by certain limitations, which are associated with the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs have been recently introduced, to overcome these boundaries. The concept of these systems is defined by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to expand the available pool of raw materials and pharmaceutical applications of FFF.

Original languageEnglish
JournalExpert Opinion on Drug Delivery
Volume17
Issue number8
Pages (from-to)1063-1067
ISSN1742-5247
DOIs
Publication statusPublished - 2020

Keywords

  • 3D printing
  • automated filling
  • biologics
  • electrospinning
  • fused filament fabrication
  • hybrid systems
  • injection molding
  • inkjet printing

Cite this